Prof. Glenwood Goss said adjuvant durvalumab did not improve disease-free survival outcomes following complete resection and optional chemotherapy. Read more
Dr. Mike Gieske said since implementing a multidisciplinary screening approach, his healthcare system has seen a 19% decrease in late-stage lung cancers, and they now see more early-stage than late-stage lung cancers. Read more
Nine difference-makers in the field of lung cancer shared their groundbreaking work during the IASLC Lectureship Awards presentations at WCLC 2024. Read more
European Medicines Agency recommends repotrectinib for ROS1-positive NSCLC; FDA approves therapies for NSCLC, LS-SCLC as well as a new diagnostic tool for identifying MET exon 14 skipping alterations. Read more
Prof. Benjamin Besse said the TKI showed encouraging clinical activity in patients who were heavily pre-treated. Read more
Dr. Alexander Drilon said most patients with ALK-positive NSCLC treated with NVL-655 showed disease regression and deep responses. Read more
Dr. Matt Warkentin says in those without significant comorbidity and who are fit for surgery, screening may provide survival benefits. Read more
Dr. Katie Smith says pragmatic clinical trials reveal the impact of symptom burden in young patients. Read more
Dr. Li said a considerable global burden of asbestos-related lung cancers and mesothelioma persists, even as beneficial impact of national asbestos bans are awaited. Read more